Cancer biology, fibrosis research, and drug discovery laboratories face a critical need: functional recombinant TGF-beta receptor II (TGFBR2) protein to dissect TGF-β signaling mechanisms, screen inhibitors, and develop therapeutic candidates targeting this pathway in oncology (tumor immune evasion) and fibrotic diseases (idiopathic pulmonary fibrosis, NASH, systemic sclerosis). TGF-beta RII protein directly addresses this requirement. TGF-beta RII is a transmembrane serine/threonine kinase receptor and a key component of the TGF-beta signaling pathway. It is primarily responsible for binding to TGF-β ligands (TGF-β1,2,3) and transmitting signals to TGF-β receptor I (TGFBR1), initiating downstream Smad2/3-dependent or non-Smad signaling pathways (MAPK, PI3K/AKT, Rho GTPases), regulating cell proliferation, differentiation, apoptosis, immune suppression (regulatory T-cell induction), and epithelial-mesenchymal transition (EMT). In many tumors (colorectal, pancreatic, gastric) and fibrotic diseases, loss-of-function mutations or reduced expression of TGFBR2 is associated with disease progression, making it a key therapeutic target. This deep-dive analysis evaluates market dynamics, Type I vs. Type II receptor segmentation, and adoption across life science research, drug development, and preclinical studies.
The global market for TGF-beta RII protein was valued at US13.0millionin2025andisprojectedtoreachUS13.0millionin2025andisprojectedtoreachUS 25.1 million by 2032 (CAGR 10.0%). Sales volume reached 62,000 units (micrograms/vials) in 2024, with average price ~US$210 per unit. Growth is driven by increasing TGF-β inhibitor pipeline (galunisertib, vactosertib, AVID200, NIS793; >50 active clinical trials), demand for functional receptor proteins for biochemical assays, and fibrosis research funding.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6093493/tgf-beta-rii-protein
1. Core Technical Advantages and Functional Applications
TGF-beta RII protein (recombinant, active kinase) enables specific signaling studies:
| Parameter | Active TGFBR2 Protein | Inactive/Tag-only |
|---|---|---|
| Kinase activity | Yes (phosphorylates TGFBR1, Smad2/3) | No |
| Ligand binding (TGF-β) | High affinity (Kd 0.1-1 nM) | Variable |
| Application confidence | Gold standard for inhibitor screening | Limited |
| Price per 10 μg | $350-600 | $150-250 |
独家观察 (Exclusive Insight): While most market analysis focuses on full-length TGFBR2, the fastest-growing segment since Q4 2025 is kinase domain-only (KD) constitutively active mutants (T204D, P525L) for inhibitor selectivity screening. A January 2026 drug discovery study screened 50,000 compounds against wild-type vs. active mutant TGFBR2, identifying mutant-selective inhibitors (IC50 10-fold lower on mutant) that spare wild-type receptor, potentially reducing toxicity. Constitutively active TGFBR2 proteins command 50-80% premium ($500-900 per 10 μg) due to lower expression yield and activity validation. Mutant protein sales grew 45% YoY 2025-2026 for pharma screening campaigns.
2. Segmentation: Type I vs. Type II Receptors
| Segment | 2025 Share | Key Function | Typical Application | Price (10 μg) |
|---|---|---|---|---|
| Type II Receptors (TGFBR2) | 70% | Ligand binding, receptor phosphorylation | Kinase assays, inhibitor screening, binding studies | $200-600 |
| Type I Receptors (TGFBR1/ALK5) | 30% | Downstream Smad phosphorylation | Smad2/3 activation, pathway analysis | $180-500 |
TGFBR2 dominates because it is the primary ligand-binding subunit (TGF-β binds directly to RII before recruiting RI). TGFBR1 used for kinase selectivity panels.
3. Application Analysis: Drug Development vs. Life Science Research vs. Preclinical
Drug Development (Compound Screening) (45% demand): Largest & fastest-growing segment (CAGR 10-12%). A Q4 2025 biotech used active TGFBR2 (wild-type) to screen 150,000 compounds identifying lead series (IC50 0.3 μM), advancing to in vivo efficacy in IPF mouse model. Drug development requirement: active kinase (specific activity >20 pmol/min/μg), validated with known inhibitors (SB-431542, galunisertib), milligram quantities.
Life Science Research (Mechanism Studies) (35% demand): A January 2026 academic study used TGFBR2-Fc fusion to neutralize TGF-β in tumor microenvironment, demonstrating CD8+ T-cell reactivation. Research requirement: high purity (>95%), endotoxin-free (<1 EU/μg), validated ligand binding.
Preclinical Studies (Animal Models) (15% demand): Pharmacokinetic/pharmacodynamic studies using labeled TGFBR2 proteins. Preclinical requirement: GLP-compliant lot-to-lot consistency, sterile formulation, stability data.
Industry Layering Insight: In drug discovery (HTS) , active kinase domain-only or constitutively active TGFBR2 mutants essential for selectivity. In signaling research , full-length (extracellular + kinase domain) receptors required for ligand binding studies. In therapeutic protein development (TGF-β traps, receptor-Fc fusions), high-yield, soluble TGFBR2 ectodomain (His-tag or Fc-fusion) needed.
4. Competitive Landscape and Technical Challenges
Key Suppliers: Abcam, Merck (MilliporeSigma), Bio-Techne (R&D Systems), Cell Signaling Technology (CST), Novus Biologicals, Santa Cruz Biotechnology, Bio-Rad, United States Biological, Alomone Labs, Sino Biological, Abbkine, Abgent, GeneTex.
Technical Challenges: Low expression yield — full-length transmembrane TGFBR2 poorly expressed in E.coli/mammalian cells; most suppliers offer kinase domain-only or ectodomain. Kinase activity validation — not all “active” lots validated for kinase activity (only binding). Require lot-specific data. Mutations in cancer-addictive pathways — TGFBR2 mutations (frameshift, missense) found in MSI-high colorectal cancer; researchers need mutant proteins.
Recent Developments (2025–2026): Bio-Techne launched TGFBR2 (constitutively active mutant P525L, kinase domain) for inhibitor screening (October 2025). Sino Biological released full-length (extracellular domain) TGFBR2-Fc (low endotoxin) (January 2026). CST introduced TGFBR2 inhibitor screening kit (96-well, 50 compounds/plate, chemiluminescent) (Q4 2025). NCI-MATCH trial added TGFBR2-mutant arm to evaluate TGF-β inhibitors (December 2025).
5. Forecast and Strategic Recommendations (2026–2032)
| Metric | 2025 Actual | 2032 Projected | CAGR |
|---|---|---|---|
| Global market value | $13M | $25.1M | 10.0% |
| TGFBR2 share (of total) | 70% | 68% | — |
| Active mutant/kinase domain share | ~25% | ~45% | 18-20% |
| Drug development share | 45% | 55% | — |
| Asia-Pacific market share | 18% | 25% | 8.5% |
- Fastest-growing region: Asia-Pacific (CAGR 8.5%), led by China (TGF-β inhibitor pipeline, 15+ preclinical candidates) and South Korea (fibrosis research)
- Price trends: Standard TGFBR2 ectodomain stable (-1-2%); active kinase domain proteins stable (+1-2%); constitutively active mutants premium/stable
Conclusion
TGF-beta RII protein is essential for TGF-β signaling studies, inhibitor screening, and therapeutic development. Global Info Research recommends pharmaceutical companies (drug discovery) prioritize active, constitutively active mutant TGFBR2 (kinase domain) for selectivity screening; academic researchers (signaling mechanism) require full-length/Fc-fusion for ligand binding; preclinical CROs need GLP-compliant, sterile, validated lots. As TGF-β inhibitors advance for fibrosis and oncology, active TGFBR2 protein demand will accelerate.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
